- Home
- PEBK vs ELTX Comparison
PEBK vs ELTX Comparison
Compare PEBK & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | ELTX |
|---|---|---|
| Founded | 1912 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.0M | 209.9M |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PEBK | ELTX |
|---|---|---|
| Price | $39.81 | $10.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 17.9K | ★ 126.8K |
| Earning Date | 04-20-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | 21.48 | ★ 39.29 |
| EPS | ★ 3.62 | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.96 | $4.60 |
| 52 Week High | $40.74 | $14.93 |
Technical Indicators
Market Signals| Indicator | PEBK | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 48.54 |
| Support Level | $35.24 | $9.84 |
| Resistance Level | $39.66 | $11.12 |
| Average True Range (ATR) | 0.86 | 0.97 |
| MACD | 0.17 | -0.23 |
| Stochastic Oscillator | 88.16 | 26.92 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.